Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (6.003.930 €): Mitgestaltung und Durchführung einer Intervention zur Verbesserung des Verständnisses von Hoden-Späteffekten und unerfüllten unterstützenden CarENeeDs von AYA-Überlebenden … Hor19.05.2025 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Mitgestaltung und Durchführung einer Intervention zur Verbesserung des Verständnisses von Hoden-Späteffekten und unerfüllten unterstützenden CarENeeDs von AYA-Überlebenden unter Verwendung von eXtended Reality.
"CHALLENGE: Adolescence and early adulthood are critical stages for development. A diagnosis of a life-threating disease like cancer in adolescents and young adults (AYAs), coupled with immediate and late effects of treatment, force AYAs to face mortality early in life. Testicular Cancer (TC) is the most diagnosed cancer in AYAs assigned male at birth aged 15-39 years. The incidence of TC has doubled over the last four decades, with highest incidence rates in individuals of European ancestry. Interventions to educate and support AYA TC survivors, and reduce symptom burden and late effects of TC treatment should be prioritised. SOLUTION: Project TRANSCEND-XR will ethically co-create, test, and scale up in real-life settings an innovative digital intervention to increase AYA TC survivors’ knowledge of the late effects of TesticulaR cANcer treatment and address their unmet Supportive CarE NeeDs using eXtended Reality. PLAN: TRANSCEND-XR will ensure that (i) the needs of AYA TC survivors, their care partners, and healthcare professionals are explored and disparities addressed; (ii) the TRANSCEND-XR intervention is robustly and ethically co-created, refined, and validated; (iii) there is understanding of intervention effectiveness, cost-effectiveness, process of delivery, and what AYA TC survivors ethically value about it in real-life settings. Evidence-based plans to translate knowledge into practice and policy, exploit outputs, and sustain TRANSCEND-XR in long-term, robust governance and effective patient and public involvement are established. IMPACT: TRANSCEND-XR will revolutionise the understanding and management of late effects from TC treatment among AYA survivors, improving their quality of life, throughout Europe. It will serve as a proof of concept for ethically developing, evaluating, and implementing immersive educational digital health solutions to support AYA cancer survivors. This action is part of the Cancer Mission cluster of projects on “Quality of life (AYA)""."
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Academisch Ziekenhuis Groningen | 214.514 € |
| Association Europeenne des Ligues Contre le Cancer ASBL | 149.000 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 230.685 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 195.813 € |
| Fundtoinnovate Ltd. | 474.335 € |
| Institut Gustave Roussy | 1.004.688 € |
| Khora ApS | 626.006 € |
| Predictby Research And Consulting SL | 202.500 € |
| Sveuciliste U Zagrebu Medicinski Fakultet | 158.825 € |
| The Adelaide & Meath Hospital Dublin Incorporating the National Children's Hospital | 74.006 € |
| The Queen's University of Belfast | 613.999 € |
| The Royal Marsden National Health Service Trust | 203.780 € |
| Universidade Catolica Portuguesa | 421.700 € |
| University College Cork - National University of Ireland, Cork | 1.247.205 € |
| Univerzita Komenskeho V Bratislave | 186.875 € |
Quelle: https://cordis.europa.eu/project/id/101214413
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.